Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical and Health Comprehensive Index has shown significant growth, with a year-to-date increase of 85.26% [1]. Group 1: Index Performance - The Shanghai Composite Index decreased by 0.37%, while the Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 2.51%, closing at 3658.84 points with a trading volume of 24.507 billion yuan [1]. - Over the past month, the Hong Kong Stock Connect Medical and Health Comprehensive Index has risen by 24.02%, and over the last three months, it has increased by 47.29% [1]. Group 2: Index Composition - The index comprises 50 liquid and large-cap medical and health industry companies listed within the Hong Kong Stock Connect, reflecting the overall performance of these securities [1]. - The index was established on November 14, 2014, with a base point of 3000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: - Innovent Biologics (10.25%) - WuXi Biologics (9.23%) - BeiGene (8.95%) - CanSino Biologics (8.12%) - China Biologic Products (5.97%) - CSPC Pharmaceutical Group (5.77%) - JD Health (4.52%) - 3SBio (4.19%) - Hansoh Pharmaceutical (3.0%) - WuXi AppTec (2.85%) [1]. Group 4: Market and Sector Allocation - The index's holdings are entirely composed of securities listed on the Hong Kong Stock Exchange, with a 100% allocation to the medical and health sector [1].

科创创业ETF（588360）跟踪的是科创创业50指数（931643），当日涨跌幅可达20%。该指数从科 创板和创业板中选取市值较大、流动性较好的50只证券作为指数样本，以反映科技创新领域上市公司证 券的整体表现。该指数覆盖信息技术、医药卫生等多个行业，具有显著的成长性和创新性特征。 没有股票账户的投资者可关注国泰中证科创创业50ETF发起联接C（013307），国泰中证科创创业 50ETF发起联接A（013306）。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不 预示未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参 考，不构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险 等级相匹配的产品。基金有风险，投资需谨慎。 每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun. ...

Group 1 - The technology sector is expected to attract funds flowing from "anti-involution" and infrastructure sectors, supported by ongoing policy narratives [1] - The AI industry is becoming increasingly competitive with the release of Grok4 and the upcoming launch of GPT-5, while the lifting of restrictions on H20 chips will encourage domestic companies to increase R&D [1] - The semiconductor sector has room for rebound, with the Science and Technology Innovation 50 Index still at a low level since February, and expectations for IPOs of domestic GPU companies and government procurement may drive market activity [1] Group 2 - The focus on robotics is increasing, and inflation expectations do not have a direct impact on technology logic; industry progress remains the core driver [1] - The TMT (Technology, Media, and Telecommunications) sector is currently less crowded, and specific technology sub-sectors may benefit from unexpected positive developments [1] - The Science and Technology Innovation and Entrepreneurship ETF (588360) tracks the Science and Technology Innovation 50 Index (931643), which includes 50 securities with larger market capitalization and better liquidity from the Science and Technology Board and the Growth Enterprise Market [1]

Group 1 - The core viewpoint of the article highlights the performance of the China Securities Hong Kong Technology Index, which has shown significant growth, with a year-to-date increase of 35.11% [1] - The index consists of 50 large-cap technology companies listed in Hong Kong, selected based on their market capitalization, R&D investment, and revenue growth [1] - The top ten weighted companies in the index include Xiaomi Group-W (10.24%), Tencent Holdings (9.72%), Alibaba-W (9.62%), Meituan-W (8.32%), BYD Company (7.9%), NetEase-S (6.81%), JD Group-SW (6.59%), Baidu Group-SW (3.98%), SMIC (3.72%), and Kuaishou-W (3.49%) [1] Group 2 - The sector distribution of the index's holdings shows that consumer discretionary accounts for 41.28%, communication services for 26.09%, information technology for 21.39%, healthcare for 10.79%, and industrials for 0.45% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Public funds tracking the Hong Kong technology sector include the Southern China Securities Hong Kong Technology ETF and the China Merchants Securities Hong Kong Technology ETF [3]

Core Insights - The recent performance of the ChiNext 50 industry has shown divergence, with technology growth assets exhibiting higher elasticity during periods of liquidity easing [1] - As U.S. Treasury yields retreat from high levels, the success rate of trading domestic AI computing and "hard technology" has increased [1] - The relative PE of ChiNext to CSI 300 has risen from 4.84 to 4.92, and the relative PB has increased from 2.58 to 2.61, indicating a valuation recovery in the growth sector [1] Group 1 - The ChiNext 50 ETF managed by Guotai tracks the ChiNext 50 Index, which can experience daily fluctuations of up to 20% [1] - The ChiNext 50 Index, published by the Shenzhen Stock Exchange, selects 50 representative companies from the ChiNext market based on market capitalization and liquidity [1] - The index reflects the overall performance of China's high-growth emerging enterprises, covering multiple sectors including information technology and healthcare, with a focus on growth style [1]

Core Viewpoint - The Shenzhen Stock Exchange has announced a significant reform for the ChiNext Composite Index, which involves removing ST stocks and companies with poor ESG performance, enhancing the overall quality of the index and its constituents [3][4]. Group 1: Index Reform Details - The reform will remove ST stocks monthly, ensuring that any company labeled as ST will exit the index the following month [3]. - Companies with an ESG rating below C will be excluded, improving the index's resilience by eliminating firms with environmental, social, or governance issues [3]. - The number of sample stocks will increase from over 1,300 to 1,316, broadening the index's coverage [3]. Group 2: Industry Composition - The top three sectors represented in the index are industrial, information technology, and healthcare, which together account for 70% of the index [3]. - High-tech enterprises make up 92% of the index, while strategic emerging industries represent 79%, indicating a strong focus on innovation and future growth sectors [3]. Group 3: Historical Performance and Investment Implications - Over the past 15 years, the ChiNext Composite Index has increased by 197%, with an annualized return of 7.6%, and has risen by 10% this year [4]. - Current valuations, particularly in the healthcare and renewable energy sectors, are at historical lows, presenting potential buying opportunities [4]. - The reform is expected to make index funds more attractive, with over 200 billion yuan in products tracking the "Chuang" series index, and increased liquidity anticipated for ETFs like the Wanjiada ChiNext Composite ETF [4]. Group 4: Investment Strategy Recommendations - Investors are encouraged to consider adding ChiNext Composite ETFs to their portfolios, especially those newly included high-quality companies, which may benefit from an "inclusion effect" [4]. - A cautious approach is advised during market fluctuations, suggesting a strategy of incremental buying rather than chasing high prices [4].

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Consumer Theme has shown a mixed performance, with a recent increase but a decline over the past month, indicating volatility in the consumer sector [1][2]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Consumer Theme rose by 0.58% to 3094.05 points, with a trading volume of 51.969 billion [1]. - Over the past month, the index has decreased by 6.35%, while it has increased by 9.12% over the last three months and 17.94% year-to-date [1]. Group 2: Index Composition - The index comprises up to 50 eligible Hong Kong-listed companies that align with the consumer theme, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include Alibaba-W (13.98%), Meituan-W (12.71%), BYD Company (9.52%), and others, with a total weight of 70.3% for the top three [1]. Group 3: Sector Allocation - The index's holdings are primarily in the consumer discretionary sector, which accounts for 72.68%, followed by healthcare at 17.54% and consumer staples at 9.78% [2]. - The index is adjusted semi-annually, with changes implemented on the next trading day after the second Friday of June and December [2]. Group 4: Fund Tracking - Public funds tracking the index include Taikang China Securities Hong Kong Stock Connect Consumer Theme A and C [3].

Group 1 - The Shenzhen Stock Exchange has revised the compilation plan for the ChiNext Composite Index, resulting in a total of 1,316 sample stocks that cover 95% of the listed companies on the ChiNext board [1] - The total market capitalization coverage of these sample stocks is 98%, with the top three industries represented being Industrial (32%), Information Technology (26%), and Healthcare (12%) [1] - High-tech enterprises account for 92% of the index weight, while strategic emerging industries represent 79%, and key sectors such as advanced manufacturing, digital economy, and green low-carbon industries make up 74% [1] Group 2 - The Shenzhen Stock Exchange aims to enhance the "Chuang" series of indices and index products, focusing on serving national major strategies and key areas [1] - The exchange plans to enrich the supply of quality investment targets to provide diversified options for medium- and long-term capital allocation, contributing to the high-quality development of the capital market [1]

Group 1 - The core index, the CSI Hong Kong-Shenzhen IoT Theme Index, has shown a decline of 0.01% to 4146.62 points with a trading volume of 58.01 billion yuan [1] - Over the past month, the index has decreased by 2.24%, and over the last three months, it has fallen by 11.73%, while year-to-date it has increased by 2.30% [1] - The index comprises companies involved in IoT-related information collection, transmission, and computing, reflecting the overall performance of IoT-related listed companies in the mainland and Hong Kong markets [1] Group 2 - The top ten weighted companies in the index include Luxshare Precision (5.52%), Midea Group (5.19%), Xiaomi Group-W (5.14%), Tencent Holdings (5.03%), Meituan-W (4.47%), Li Auto-W (4.38%), Xpeng Motors-W (4.13%), China Telecom (4.02%), Huichuan Technology (3.82%), and Zhongji Xuchuang (3.77%) [1] - The market share of the index's holdings is distributed as follows: Shenzhen Stock Exchange 41.44%, Hong Kong Stock Exchange 32.67%, and Shanghai Stock Exchange 25.90% [1] Group 3 - The industry composition of the index's holdings shows that Information Technology accounts for 45.69%, Communication Services 25.15%, Consumer Discretionary 21.19%, Industrials 5.61%, and Healthcare 2.35% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Public funds tracking the SHS IoT index include Tianhong CSI Hong Kong-Shenzhen IoT Theme Connection A, Tianhong CSI Hong Kong-Shenzhen IoT Theme Connection C, and Tianhong CSI Hong Kong-Shenzhen IoT Theme ETF [2]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing positive momentum, driven by significant developments in innovative drug approvals and collaborations, particularly highlighted during the recent ASCO annual meeting and the announcement of potential licensing deals by major companies [1][2]. Group 1: Market Performance - As of June 13, 2025, the CSI Hong Kong Pharmaceutical and Health Comprehensive Index (930965) saw notable increases in key stocks, including WuXi Biologics (02269) up by 5.41%, and Innovent Biologics (01801) up by 3.53% [1]. - The Hong Kong Medical ETF (513700) rose by 1.28%, with a cumulative increase of 12.57% over the past week as of June 12, 2025 [1][2]. Group 2: Industry Developments - On June 12, 2025, China Biopharmaceutical announced at the 46th Goldman Sachs Global Healthcare Conference in Miami that it has received multiple collaboration intentions for its products, indicating a significant upcoming licensing deal [1]. - The ASCO annual meeting showcased the competitiveness and innovation of Chinese pharmaceutical companies, with several impressive results and data presentations [2]. Group 3: ETF and Index Information - The Hong Kong Medical ETF (513700) effectively tracks the CSI Hong Kong Pharmaceutical and Health Comprehensive Index, which includes 50 liquid and large-cap healthcare companies to reflect the overall performance of the sector [2]. - The top ten weighted stocks in the CSI Hong Kong Pharmaceutical and Health Comprehensive Index as of May 30, 2025, include companies like BeiGene (06160) and WuXi Biologics (02269), collectively accounting for 60.77% of the index [3].